Melanoma Prevalence Rate Grew Considerably, States GBI Research in Its In-demand Report Now Available at MarketPublishers.com
16 Feb 2017 • by Natalie Aster
LONDON – Worldwide prevalence rates of melanoma have witnessed a considerable rise during the past few decades, mainly owing to a hike in the exposure to ultraviolet (UV) radiation and/or daylight. This has led to a hike in the developmental interest pertaining to the enhancement of disease management, specifically in its advanced phase.
During the past ten years the introduction of new targeted therapies and treatments aimed at manipulating the immune response has resulted in the improvement of treatment modes for patients. These novel classes of drugs have seen an extreme commercial success with blockbuster medicines that are currently well entrenched in the treatment algorithm.
Notwithstanding these developments, there remain considerable unmet needs for both extracutaneous and cutaneous types of melanoma, and there is a strong rationale for investment in first-in-class innovation. Pioneer products grab a huge share of the total melanoma pipeline, which is far larger than the market of today.
Topical market report “Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation” prepared by GBI Research examines the market on a global level.
It provides an all-round analysis of the disease pathogenesis, prognosis, diagnosis, and the presently available treatment strategies. The study sheds light on the composition of the melanoma marketplace with respect to the leading therapy classes, and highlights unmet needs. The study canvasses the melanoma pipeline and categorises pipeline therapies by phase of development, type of molecule, and based on molecular target. It gives an assessment of the therapeutic potential of first-in-class targets, focusing specifically on an analysis of the promising new targets. Furthermore, it evaluates the versatile commercial opportunities in the melanoma co-development and licensing deals landscape.
More insightful market reports by our partner are available at GBI Research page.